<DOC>
	<DOCNO>NCT01230476</DOCNO>
	<brief_summary>Standard care treatment nasopharyngeal carcinoma chemoradiation concurrent cisplatin . Addition second agent , cetuximab , target nasopharyngeal carcinoma cell high EGFR protein expression , may enhance effectiveness radiation result well tumour control . This study investigate addition 2 cycle cisplatin/5FU chemotherapy cetuximab , follow cisplatin cetuximab concurrent radiation , treatment locally advanced nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Induction Concurrent Chemoradiotherapy With Cetuximab Patients With Locally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed write informed consent Inpatients outpatient , 1865 year age Histologically confirm , newly diagnose locally advanced ( UICC/AJCC stage III IVB ) nasopharyngeal carcinoma require radiotherapy Evidence unidimensional measurable disease per RECIST criteria No systemic metastatic disease ( M0 ) ECOG performance status 0 1 study entry Effective contraception White blood cell count ≥ 3,000/mm3 neutrophil ≥1,500/mm3 , platelet count ≥100,000/mm3 , hemoglobin ≥ 5.6 mmol/L ( 9 g/dL ) Total bilirubin ≤ 1.5x upper reference range AST &amp; ALT ≤ 1.5x upper reference range Glomerular filtration rate &gt; 60 ml/min Serum creatinine ≤ 1.25x upper reference range Previous radiotherapy , chemotherapy , surgery ( exclude diagnostic biopsy ) investigational drug NPC Concurrent chronic systemic immune therapy , target therapy , antiVEGF therapy EGFRpathway target therapy indicate study protocol Known hypersensitivity reaction component study treatment Pregnancy lactation period Systemic metastatic disease Clinically relevant coronary artery disease , history myocardial infarction last 12 month , high risk uncontrolled arrhythmia Peripheral neuropathy &gt; grade 1 Previous malignancy except basal cell cancer skin preinvasive cancer cervix Known alcohol drug abuse Medical psychological condition would permit patient complete study sign inform consent Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Locally advanced nasopharyngeal carcinoma</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>Cetuximab</keyword>
</DOC>